Tag Archives: Cancer
MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma.
Authors: de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, De Rosa G, Virgilio A, Scognamiglio I, Sciro M, Basso G, Schulte JH, Cinalli G, Iolascon A, Zollo M.
Citation: PLoS One. 2011;6(9):e24584.
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
Authors: Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.
Citation: Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43.
Re-expression of the methylated EDNRB gene in oral squamous cell carcinoma attenuates cancer-induced pain.
Authors: Viet CT, Ye Y, Dang D, Lam DK, Achdjian S, Zhang J, Schmidt BL.
Citation: Pain. 2011 Oct;152(10):2323-32.
Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.
Authors: Yue WY, Clark JJ, Fernando A, Domann F, Hansen MR.
Citation: Neuro Oncol. 2011 Sep;13(9):961-73.
A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.
Authors: Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC.
Citation: Gene Ther. 2010 Nov;17(11):1325-32.
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.
Authors: Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD.
Citation: Gene Ther. 2010 Aug;17(8):1000-10.
Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid.
Authors: Chu R, Zhao X, Griffin C, Staub RE, Shoemaker M, Climent J, Leitman D, Cohen I, Shtivelman E, Fong S.
Citation: Int J Cancer. 2010 Sep 1;127(5):1209-19.
INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.
Authors: Wang HW, Breslin MB, Chen C, Akerstrom V, Zhong Q, Lan MS.
Citation: Hum Gene Ther. 2009 Nov;20(11):1308-18.
Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
Authors: Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris JC 3rd.
Citation: Breast Cancer Res. 2009;11(4):R53.
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors
Authors: Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M
Citation: Genes Dev 2007 Feb 15 21 4: 379-384
References
Links
- Recombinant DNA and Gene Transfer Office of Biotechnology Activities http://www4.od.nih.gov/oba/Rdna.htm
- Aldevron http://www.aldevron.com/
- Bio Research Products http://www.bio-researchprod.com/home.html
- Elmira Biologicals Inc. http://www.elmirbiol.com
- Genetel Laboratories LLC http://www.genetel-lab.com/
- Midwest Bio Services http://www.midwestbioservices.com/
- Nature Technology Corporation http://www.natx.com
- Trans Ova Genetics http://www.transova.com/
Contact us
PO Box 525, North Liberty, IA 52317
Phone: 319-665-4190 | Fax: 319-665-4191
help@viraquest.com